Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

被引：103
|
作者：
Russell-Jones, David [1 ]
机构：
[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford GU2 7XX, Surrey, England
来源：
MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2009年 / 297卷 / 1-2期
关键词：
GLP-1; analogue; Hypoglycaemia; Body weight; Systolic blood pressure; GLUCAGON-LIKE PEPTIDE-1; GLYCEMIC CONTROL; GENE-EXPRESSION; BETA-CELLS; DERIVATIVES; WEIGHT; SULFONYLUREA; NN2211;
D O I：
10.1016/j.mce.2008.11.018
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical Studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：137 / 140
页数：4
相关论文
共 50 条
  • [31] The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
    Lykkegaard, Kirsten
    Larsen, Philip J.
    Vrang, Niels
    Bock, Camilla
    Bock, Troels
    Knudsen, Lotte Bjerre
    SCHIZOPHRENIA RESEARCH, 2008, 103 (1-3) : 94 - 103
  • [32] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2012, 36 : 843 - 854
  • [33] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    Aimaretti, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (08) : 701 - 703
  • [34] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    G. Aimaretti
    Journal of Endocrinological Investigation, 2009, 32 : 701 - 703
  • [35] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012)
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Roessner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 890 - 890
  • [36] Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with glimepiride: all as monotherapy in type 2 diabetes
    Garber, A.
    Henry, R.
    Ratner, R.
    Garcia-Hernandez, P.
    Pattzi, H. M. Rodriguez
    Olvera-Alvarez, I.
    Hale, P. M.
    Zdravkovic, M.
    Bode, B.
    DIABETOLOGIA, 2008, 51 : S358 - S359
  • [37] Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial
    Finer, N.
    Al Hakim, M.
    Astrup, A.
    Harper, A.
    Lean, M.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Van Gaal, L.
    DIABETOLOGIA, 2009, 52 : S11 - S12
  • [38] The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
    Flint, A.
    Kapitza, C.
    Zdravkovic, M.
    DIABETES OBESITY & METABOLISM, 2013, 15 (10): : 958 - 962
  • [39] In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss
    Fonseca, V. A.
    Henry, R. R.
    Tabanera y Palacios, R.
    Brett, J.
    Plutzky, J.
    DIABETOLOGIA, 2010, 53
  • [40] Liraglutide, a Once-Daily Human GLP-1 Analog, Lowers Systolic Blood Pressure (SBP) Independently of Concomitant Antihypertensive Treatment
    Fonseca, Vivian
    Plutzky, Jorge
    Montanya, Eduard
    Colagiuri, Stephen
    Hansen, Charlotte
    Falahati, Ali
    Devries, J. Hans
    DIABETES, 2010, 59 : A79 - A79
12345